Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$161.97 USD

161.97
575,208

+1.87 (1.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 6% (16 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

NextGen (NXGN) Extends Agreement to Boost Athletico's Footprint

by Zacks Equity Research

NextGen's (NXGN) latest extended agreement is likely to reflect its solutions' potential to aid healthcare organizations at all stages of growth.

Here's Why Investors Should Invest in Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) on strong growth in the Diagnostics business and upbeat guidance.

QIAGEN (QGEN) Extends QIAwave Product Line With New Kit

by Zacks Equity Research

QIAGEN's (QGEN) new QIAwave kits broaden its selection of environmentally friendly products and reaffirm its commitment to helping researchers advance science.

QuidelOrtho's (QDEL) Rapid Antigen Test Gets CLIA Waiver

by Zacks Equity Research

QuidelOrtho's (QDEL) receipt of the FDA's CLIA waiver is expected to widen access to the rapid antigen test in any point-of-care setting equipped with Sofia 2 instruments.

3 Reasons to Hold HealthEquity (HQY) Stock in Your Portfolio

by Zacks Equity Research

HealthEquity's (HQY) strength in HSA raises optimism about the stock.

Abbott (ABT) Closes Acquisition Deal of Bigfoot Biomedical

by Zacks Equity Research

Abbott's (ABT) footprint in the diabetes care market is increased by the Bigfoot Biomedical acquisition.

3 Reasons to Hold Veeva Systems (VEEV) Stock in Your Portfolio

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

Vasundhara Sawalka headshot

4 Stocks Trading Near 52-Week High That Can Climb Further

by Vasundhara Sawalka

Investors target stocks that have been on a bullish run lately. Stocks like GIII, CEG, CWCO and DVA that are seeing price strength have a high chance of carrying the momentum forward.

McKesson (MCK) Announces Availability of FDA-Cleared Drug for MF

by Zacks Equity Research

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for MF.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how DaVita HealthCare (DVA) and McKesson (MCK) have performed compared to their sector so far this year.

Here's Why You Should Hold BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches raises optimism about the stock.

Inogen (INGN) Completes Buyout Deal to Expand Product Portfolio

by Zacks Equity Research

Inogen's (INGN) latest acquisition is expected to expand its global Respiratory Care presence and potentially address a large growing bronchiectasis market.

New Strong Buy Stocks for September 19th

by Zacks Equity Research

DHI, DVA, KMTUY, ELAN and BWMX have been added to the Zacks Rank #1 (Strong Buy) List on September 19, 2023.

Three Reasons to Add DaVita (DVA) Stock to Your Portfolio

by Zacks Equity Research

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

DVA or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Stryker's (SYK) New Camera Platform to Improve Surgery Outcomes

by Zacks Equity Research

Stryker's (SYK) latest camera platform is likely to enhance the surgical experience across specialties.

Veeva Systems' (VEEV) New Release to Address Supply-Chain Issues

by Zacks Equity Research

Veeva Systems' (VEEV) new cloud application is likely to improve efficiency and accelerate time-to-market by connecting systems and automating data aggregation, reviews and traceability.

Should Value Investors Buy DaVita (DVA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations

by Zacks Equity Research

OPKO Health's (OPK) latest Research Collaboration Agreement is likely to enable it to expand its pipeline to develop orally administered tablet presentations of long-acting peptides.

3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio

by Zacks Equity Research

QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.

Surmodics (SRDX) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Surmodics' (SRDX) consistent efforts to boost R&D.

Reasons to Add Integer Holdings (ITGR) Stock to Your Portfolio

by Zacks Equity Research

Integer Holdings' (ITGR) improving non-medical sales and a solid foothold in the broader MedTech space raise optimism about the stock.

Avantor's (AVTR) Tie-Up to Address Temperature-Specific Logistics

by Zacks Equity Research

Avantor's (AVTR) partnership is likely to meet the growing need among biopharma and life science companies for end-to-end solutions.

BD's (BDX) Tie-Up to Explore Flow Cytometry for Clinical Outcomes

by Zacks Equity Research

BD's (BDX) latest partnership is likely to accelerate the delivery of innovative personalized therapies to patients who need them the most.